Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LY0C
|
|||
| Former ID |
DIB003887
|
|||
| Drug Name |
Radiolabelled-huA33
|
|||
| Synonyms |
Radiolabelled-huA33 (colorectal cancer); Radiolabelled-huA33 (colorectal cancer), Ludwig; 124I-huA33; 125I-huA33
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 1 | [1] | |
| Company |
Ludwig Institute for Cancer Research
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cell surface A33 antigen (GPA33) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00291486) Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health. | |||
| REF 2 | (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011 Aug;52(8):1173-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.